Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
Boehringer Ingelheim and Zealand Pharma announced the initiation of two Phase 2 clinical trials for the GLP-1/glucagon dual agonist BI 456906 targeting obesity and non-alcoholic steatohepatitis (NASH). This advancement stems from their long-term collaboration, focusing on innovative therapies for cardiometabolic diseases. The trials aim to demonstrate weight loss efficacy and improvement of liver conditions over 48 weeks. Zealand stands to gain up to EUR 345 million in milestone payments, plus royalties on global sales from BI 456906.
Zealand Pharma A/S (Nasdaq: ZEAL) announced share transactions by managerial responsibilities on April 9, 2021. The information pertains to transactions conducted by individuals associated with Zealand, reflecting the company’s ongoing share activity. Zealand Pharma focuses on developing innovative peptide-based medicines aimed at treating metabolic and gastrointestinal diseases. It has successfully advanced over 10 drug candidates into clinical development and is actively engaged in partnerships with leading pharmaceutical companies, enhancing its growth potential.
Zealand Pharma A/S has increased its share capital by DKK 21,650 through the exercise of employee warrants, resulting in the issuance of 21,650 new shares. The exercise prices were DKK 135.30 for 3,900 shares and DKK 142.45 for 17,750 shares, yielding total proceeds of DKK 3,056,157.50. The total share capital now stands at DKK 43,449,842, with shares to be listed on Nasdaq Copenhagen after registration. The new shares confer voting and dividend rights.
Zealand Pharma announced its total number of shares and voting rights as of March 31, 2021.
As per the report, the total number of shares stood at 43,428,192, reflecting the exercise of employee warrants disclosed earlier this month. This increase directly impacts the share capital, which remains at 43,428,192 DKK.
Zealand Pharma continues its focus on peptide-based medicines and has several candidates in late-stage development, with two already on the market.
Zealand Pharma (Nasdaq: ZEAL) announced participation in upcoming investor conferences in April 2021. The company's senior management will present at the Guggenheim Virtual Healthcare Talks on April 1, and at the 20th Annual Virtual Needham Healthcare Conference on April 12, with a presentation scheduled at 11:45 a.m. ET. Live webcasts will be available on the company's website, with replays archived post-event. Zealand focuses on innovative peptide-based medicines for metabolic and gastrointestinal diseases.
Zealand Pharma has received FDA approval for Zegalogue (dasiglucagon) injection, designed to treat severe hypoglycemia in diabetes patients aged 6 and older. This approval is based on clinical trials demonstrating a median recovery time of just 10 minutes after administration. Zegalogue will be available in an auto-injector and prefilled syringe format, with plans for market launch in June 2021. The drug aims to address severe hypoglycemic events, which can escalate quickly and pose significant health risks.
Zealand Pharma A/S (Nasdaq: ZEAL) announced on March 22, 2021, the disclosure of transactions involving its shares by individuals in managerial roles or closely associated persons. This disclosure is part of compliance with regulations concerning insider trading. Zealand is a biotechnology company with a strong pipeline, including multiple drug candidates in clinical development and market-approved products. Further details regarding these transactions can be found in the attached file.
Zealand Pharma has increased its share capital by DKK 27,645 through the exercise of employee warrants, resulting in the issuance of 27,645 new shares at nominal value of DKK 1 each. The total proceeds from this capital increase amount to DKK 3,911,074.75. The exercise prices for the new shares were DKK 135.30 and DKK 142.45. Following this increase, Zealand Pharma's share capital stands at DKK 43,428,192, divided into 43,428,192 shares. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority.
Zealand Pharma has scheduled its Annual General Meeting for April 15, 2021, at 3:00 pm (CEST), to be held entirely online. The agenda includes the management's report on the past financial year, approval of the audited 2020 Annual Report, election of board members, and amendments to the Remuneration Policy. A notable proposal allows acquiring treasury shares up to 10% of the company's share capital. All current board members are recommended for re-election. The meeting will be conducted in English, with further details available on the company’s website.
Zealand Pharma announced significant milestones in its 2020 financial results, achieving a revenue of DKK 353.3 million ($54.2 million), a notable increase from DKK 41.3 million ($6.2 million) in 2019. Operating losses expanded to DKK 792.4 million ($121.1 million) compared to DKK 587.9 million ($88.1 million) in 2019. Key advancements include filing a New Drug Application (NDA) for the dasiglucagon auto-injector and establishing U.S. commercial operations. The company anticipates net product revenue to reach DKK 220 million in 2021. Zealand is progressing on its clinical pipeline while facing increasing operating expenses.